A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection
NCT ID: NCT06272071
Last Updated: 2024-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
2000 participants
OBSERVATIONAL
2024-03-31
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Mapping of infectious agents in patients with severe hepatitis (liver failure)
* Constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Population-wide Research for HBV-related Liver Diseases in Maoming City
NCT06184347
Study on Gut Microbiota in Chronic HBV Infected Patients
NCT03587467
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
NCT03577938
The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B
NCT05705141
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
NCT05057065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sex is not limited and age is 18-70 years old;
3. HBsAg positive for more than 6 months, or hepatitis E IgM positive, or hepatitis E RNA positive;
4. Progressive deepening of jaundice in a short period of time (serum total bilirubin greater than 10 times the upper limit of normal or rising ≥17.1 umol/L per day);
5. Sgnificant bleeding tendency with PTA ≤ 40% and exclusion of other non-hepatic factors.
Exclusion Criteria
2. Patients who were considered by the investigator to be unsuitable for participation in the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Ditan Hospital
OTHER
Beijing YouAn Hospital
OTHER
Huashan Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiajia Chen
Chief Physician of the First Affiliated Hospital,Zhejiang University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiajia Chen
Role: PRINCIPAL_INVESTIGATOR
Zhejiang University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023YFC2308802-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.